- Home
- SILO vs CANF Comparison
SILO vs CANF Comparison
Compare SILO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | CANF |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.7M |
| IPO Year | 2011 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SILO | CANF |
|---|---|---|
| Price | $0.35 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 180.7K | 81.0K |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | $1.86 | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.17 |
| 52 Week High | $1.18 | $10.40 |
Technical Indicators
Market Signals| Indicator | SILO | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 36.89 |
| Support Level | $0.33 | $0.59 |
| Resistance Level | $0.39 | $4.74 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 42.22 | 15.89 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.